TECX

SEC source: 0001127602-20-019024 · form4.xml · derivative · entry 1

Donenberg Phillip B. · CIK 0001238120 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 14,000 shares

Expires 2030-06-03

F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 4, 2021 or the date of the Issuer's 2021 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date.

SEC source: 0001127602-20-019017 · form4.xml · derivative · entry 1

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 14,000 shares

Expires 2030-06-03

F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 4, 2021 or the date of the Issuer's 2021 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date.

SEC source: 0001127602-20-019020 · form4.xml · derivative · entry 1

Jenkins Annalisa · CIK 0001639481 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 14,000 shares

Expires 2030-06-03

F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 4, 2021 or the date of the Issuer's 2021 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date.

SEC source: 0001127602-20-009841 · form4.xml · derivative · entry 1

Volck Birgitte · CIK 0001762371 · President of R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,000

Underlying: Common Stock · 76,000 shares

Expires 2030-03-03

F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on February 3, 2021, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period.

SEC source: 0001127602-20-009843 · form4.xml · derivative · entry 1

Petersen Deanna M · CIK 0001493139 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2030-03-03

F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on February 3, 2021, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period.

SEC source: 0001127602-20-009836 · form4.xml · derivative · entry 1

Ostrowski Erik · CIK 0001762507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,900

Underlying: Common Stock · 100,900 shares

Expires 2030-03-03

F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on March 4, 2021, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period.

SEC source: 0001127602-20-009831 · form4.xml · derivative · entry 1

MACKAY GEOFFREY · CIK 0001741849 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 292,300

Underlying: Common Stock · 292,300 shares

Expires 2030-03-03

F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on March 4, 2021, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period.

SEC source: 0001127602-20-009825 · form4.xml · derivative · entry 1

Avruch Steven · CIK 0001762236 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2030-03-03

F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on February 3, 2021, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period.

SEC source: 0001209191-20-010413 · doc4.xml · nonDerivative · entry 1

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,710,052

F1 · kind: Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X") to its general partner and limited partners without additional consideration, pursuant to Atlas Venture Fund X's Rule 10b5-1 plan dated July 23, 2019.

SEC source: 0000899243-20-004746 · doc4.xml · nonDerivative · entry 1

MACKAY GEOFFREY · CIK 0001741849 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 345,123

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.32, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0000899243-20-004181 · doc4.xml · nonDerivative · entry 1

PAIGE CHRISTOPHER · CIK 0001742209 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 252,512

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0000899243-20-004179 · doc4.xml · nonDerivative · entry 2

MACKAY GEOFFREY · CIK 0001741849 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 346,523

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.35, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0000899243-20-004179 · doc4.xml · nonDerivative · entry 1

MACKAY GEOFFREY · CIK 0001741849 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 364,927

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.995, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0000899243-20-002356 · doc4.xml · nonDerivative · entry 1

PAIGE CHRISTOPHER · CIK 0001742209 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 267,512

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0000899243-20-004749 · doc5.xml · nonDerivative · entry 1

MACKAY GEOFFREY · CIK 0001741849 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,123

F1 · shares: This transaction was a bona fide gift of common stock to The Geoff R. MacKay Irrevocable Trust. The reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0000899243-19-020101 · doc4.xml · nonDerivative · entry 1

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,567,289

F1 · ownership.nature: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000899243-19-020100 · doc4.xml · nonDerivative · entry 1

Booth Bruce · CIK 0001451612 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,567,289

F1 · ownership.nature: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-19-016858 · doc4.xml · derivative · entry 1

PAIGE CHRISTOPHER · CIK 0001742209 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,675

Underlying: Common Stock · 9,675 shares

Expires 2029-06-10

F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 11, 2020 or the date of the Issuer's 2020 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date.

SEC source: 0000899243-19-016860 · doc4.xml · derivative · entry 1

Vickers Philip J. · CIK 0001635046 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,675

Underlying: Common Stock · 9,675 shares

Expires 2029-06-10

F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 11, 2020 or the date of the Issuer's 2020 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date.

SEC source: 0000899243-19-016853 · doc4.xml · derivative · entry 1

Booth Bruce · CIK 0001451612 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,675

Underlying: Common Stock · 9,675 shares

Expires 2029-06-10

F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 11, 2020 or the date of the Issuer's 2020 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date.

F2 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-19-016854 · doc4.xml · derivative · entry 1

Donenberg Phillip B. · CIK 0001238120 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,675

Underlying: Common Stock · 9,675 shares

Expires 2029-06-10

F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 11, 2020 or the date of the Issuer's 2020 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date.

SEC source: 0000899243-19-016856 · doc4.xml · derivative · entry 1

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,675

Underlying: Common Stock · 9,675 shares

Expires 2029-06-10

F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 11, 2020 or the date of the Issuer's 2020 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date.

SEC source: 0000899243-19-016855 · doc4.xml · derivative · entry 1

Jenkins Annalisa · CIK 0001639481 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,675

Underlying: Common Stock · 9,675 shares

Expires 2029-06-10

F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 11, 2020 or the date of the Issuer's 2020 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date.

SEC source: 0000899243-19-014418 · doc4.xml · nonDerivative · entry 1

Clarus Lifesciences III, L.P. · CIK 0001597143 · 10% owner

Clarus Ventures III GP, L.P. · CIK 0001620148 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,481,162

F1 · kind: Represents a distribution of shares of common stock of the issuer (the "Common Stock") previously held directly by Clarus Lifesciences III, L.P. ("Clarus III") to limited partners of Clarus III, including Clarus Ventures III GP, L.P. ("Clarus GP"), in respect of their indirect interests in Clarus III (the "Clarus III Distribution"). Clarus GP then distributed the 202,995 shares of Common Stock it received in the Clarus III Distribution to its limited partners.

F1 · price: Represents a distribution of shares of common stock of the issuer (the "Common Stock") previously held directly by Clarus Lifesciences III, L.P. ("Clarus III") to limited partners of Clarus III, including Clarus Ventures III GP, L.P. ("Clarus GP"), in respect of their indirect interests in Clarus III (the "Clarus III Distribution"). Clarus GP then distributed the 202,995 shares of Common Stock it received in the Clarus III Distribution to its limited partners.

F2 · ownership.nature: These securities are held directly by Clarus III. Clarus GP is the sole general partner of Clarus III. Blackstone Clarus III L.L.C. is the sole general partner of Clarus GP. The sole member of Blackstone Clarus III L.L.C. is Blackstone Holdings II L.P. The sole general partner of Blackstone Holdings II L.P. is Blackstone Holdings I/II GP Inc. The controlling shareholder of Blackstone Holdings I/II GP Inc. is The Blackstone Group L.P. The sole general partner of The Blackstone Group L.P. is Blackstone Group Management L.L.C. Blackstone Group Management L.L.C. is wholly-owned by Blackstone's senior managing directors and controlled by its founder, Stephen A. Schwarzman.

F3 · ownership.nature: Information with respect to each of the Reporting Persons is given solely by such Reporting Person, and no Reporting Person has responsibility for the accuracy or completeness of information supplied by another Reporting Person.

F4 · ownership.nature: Each of the Reporting Persons (other than Clarus III) disclaims beneficial ownership of the securities held by Clarus III, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, each of the Reporting Persons (other than Clarus III) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-19-010377 · doc4.xml · nonDerivative · entry 4

PAIGE CHRISTOPHER · CIK 0001742209 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 277,512

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0000899243-19-010377 · doc4.xml · nonDerivative · entry 3

PAIGE CHRISTOPHER · CIK 0001742209 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 277,612

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.64 to $26.43, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0000899243-19-010373 · doc4.xml · nonDerivative · entry 2

MACKAY GEOFFREY · CIK 0001741849 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 409,523

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.145, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0000899243-19-010377 · doc4.xml · nonDerivative · entry 2

PAIGE CHRISTOPHER · CIK 0001742209 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,012

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.40, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0000899243-19-010377 · doc4.xml · nonDerivative · entry 1

PAIGE CHRISTOPHER · CIK 0001742209 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,879

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.975 , inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0000899243-19-010373 · doc4.xml · nonDerivative · entry 1

MACKAY GEOFFREY · CIK 0001741849 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 410,221

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.75, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0000899243-19-006669 · doc4.xml · derivative · entry 1

MACKAY GEOFFREY · CIK 0001741849 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2029-03-04

F1 · derivative.exercise_date: 25% of the shares vest on March 5, 2020, and the remaining 75% shall vest in equal monthly installments thereafter over a three-year period.

SEC source: 0000899243-19-001495 · doc4.xml · nonDerivative · entry 2

SVLSF VI, LLC · CIK 0001717728 · 10% owner

SV Life Sciences Fund VI, L.P. · CIK 0001642251 · 10% owner

SV Life Sciences Fund VI Strategic Partners, L.P. · CIK 0001667605 · 10% owner

SV Life Sciences Fund VI (GP), L.P. · CIK 0001717730 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 63,913

F3 · kind: SV Life Sciences Fund VI Strategic Partners, L.P. ("SV Life SP LP") distributed the shares to its limited partners on a pro rata basis.

F4 · ownership.nature: The shares are held directly by SV Life SP LP. SV Fund VI GP is the general partner of SV Life SP LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. Each of SV Fund VI GP, and SVLSF VI, LLC disclaims beneficial ownership of the shares owned directly by SV Life SP LP, except to the extent of any pecuniary interest therein.

SEC source: 0000899243-19-001495 · doc4.xml · nonDerivative · entry 1

SVLSF VI, LLC · CIK 0001717728 · 10% owner

SV Life Sciences Fund VI, L.P. · CIK 0001642251 · 10% owner

SV Life Sciences Fund VI Strategic Partners, L.P. · CIK 0001667605 · 10% owner

SV Life Sciences Fund VI (GP), L.P. · CIK 0001717730 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,866,791

F1 · kind: SV Life Sciences Fund VI, L.P. ("SV Life LP") distributed the shares to its limited partners on a pro rata basis.

F2 · ownership.nature: The shares are held directly by SV Life LP. SV Life Sciences Fund VI (GP), L.P. ("SV Fund VI GP") is the general partner of SV Life LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. Each of SV Fund VI GP and SVLSF VI, LLC disclaims beneficial ownership of the shares owned directly by SV Life LP, except to the extent of any pecuniary interest therein.

SEC source: 0000899243-19-000842 · doc4.xml · derivative · entry 1

Vickers Philip J. · CIK 0001635046 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,743

Underlying: Common Stock · 18,743 shares

Expires 2029-01-06

F1 · derivative.exercise_date: The shares vest in 36 equal monthly installments over a three year period following January 7, 2019.

SEC source: 0000899243-19-000540 · doc4.xml · derivative · entry 1

Avruch Steven · CIK 0001762236 · VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,636

Underlying: Common Stock · 88,636 shares

Expires 2029-01-01

F1 · derivative.exercise_date: 25% of the shares vest on January 2, 2020, and the remaining 75% shall vest in equal monthly installments thereafter over a three-year period.

SEC source: 0000899243-19-000539 · doc4.xml · derivative · entry 2

Ostrowski Erik · CIK 0001762507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 186,000

Underlying: Common Stock · 186,000 shares

Expires 2029-01-01

F2 · derivative.exercise_date: 25% of the shares vest on January 2, 2020, and the remaining 75% shall vest in equal monthly installments thereafter over a three-year period.

SEC source: 0000899243-19-000539 · doc4.xml · nonDerivative · entry 1

Ostrowski Erik · CIK 0001762507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,300

F1 · shares: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of AVROBIO, Inc., common stock. The restricted stock units vest as follows: 25% of the shares vest on January 2, 2020, and the remaining 75% shall vest in equal monthly installments thereafter over a three-year period.

SEC source: 0000899243-18-031419 · doc4.xml · derivative · entry 1

Volck Birgitte · CIK 0001762371 · President of R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 293,000

Underlying: Common Stock · 293,000 shares

Expires 2028-12-16

F1 · derivative.exercise_date: 25% of the shares vest on December 17, 2019, and the remaining 75% shall vest in equal monthly installments thereafter over a three-year period.

SEC source: 0000899243-18-026516 · doc4.xml · derivative · entry 2

Dorton Katina · CIK 0001617541 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,318

Underlying: Common Stock · 10,000 shares

Expires 2027-07-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the shares vested on August 28, 2018, and the remaining 75% vest in equal monthly installments thereafter over a three-year period.

SEC source: 0000899243-18-026516 · doc4.xml · nonDerivative · entry 1

Dorton Katina · CIK 0001617541 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-18-026507 · doc4.xml · derivative · entry 2

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,629

Underlying: Common Stock · 2,942 shares

Expires 2027-06-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the shares vested on June 13, 2018 and the remaining 75% vest in equal monthly installments thereafter over a three-year period.

SEC source: 0000899243-18-026507 · doc4.xml · nonDerivative · entry 1

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,942

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-18-017965 · doc4.xml · derivative · entry 8

SVLSF VI, LLC · CIK 0001717728 · 10% owner

SV Life Sciences Fund VI, L.P. · CIK 0001642251 · 10% owner

SV Life Sciences Fund VI Strategic Partners, L.P. · CIK 0001667605 · 10% owner

SV Life Sciences Fund VI (GP), L.P. · CIK 0001717730 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 14,982 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Represents the total number of shares of Common Stock received by SV Life Sciences Fund VI Strategic Partners, L.P. ("SV Life SP LP") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

F7 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date.

F7 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date.

F4 · ownership.nature: The shares are held directly by SV Life SP LP. SV Health Investors, LLC is the Manager of SV Life SP LP. SV Fund VI GP is the general partner of SV Life SP LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. The members of the investment committee of SVLSF VI, LLC are Kate Bingham, Thomas Flynn, James Garvey, Eugene D. Hill, III, Paul LaViolette, and Michael Ross. Each of SV Fund VI GP, SVLSF VI, LLC and the SVLSF VI, LLC investment committee disclaims beneficial ownership of the shares owned directly by SV Life SP LP, except to the extent of any pecuniary interest therein.

SEC source: 0000899243-18-017965 · doc4.xml · derivative · entry 7

SVLSF VI, LLC · CIK 0001717728 · 10% owner

SV Life Sciences Fund VI, L.P. · CIK 0001642251 · 10% owner

SV Life Sciences Fund VI Strategic Partners, L.P. · CIK 0001667605 · 10% owner

SV Life Sciences Fund VI (GP), L.P. · CIK 0001717730 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 437,611 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Represents the total number of shares of Common Stock received by SV Life Sciences Fund VI Strategic Partners, L.P. ("SV Life SP LP") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

F7 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date.

F7 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date.

F2 · ownership.nature: The shares are held directly by SV Life LP. SV Health Investors, LLC is the Manager of SV Life LP. SV Life Sciences Fund VI (GP), L.P., ("SV Fund VI GP") is the general partner of SV Life LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. The members of the investment committee of SVLSF VI, LLC are Kate Bingham, Thomas Flynn, James Garvey, Eugene D. Hill, III, Paul LaViolette, and Michael Ross. Each of SV Fund VI GP, SVLSF VI, LLC and the SVLSF VI, LLC investment committee disclaims beneficial ownership of the shares owned directly by SV Life LP, except to the extent of any pecuniary interest therein.

SEC source: 0000899243-18-017965 · doc4.xml · derivative · entry 6

SVLSF VI, LLC · CIK 0001717728 · 10% owner

SV Life Sciences Fund VI, L.P. · CIK 0001642251 · 10% owner

SV Life Sciences Fund VI Strategic Partners, L.P. · CIK 0001667605 · 10% owner

SV Life Sciences Fund VI (GP), L.P. · CIK 0001717730 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 75,591 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Represents the total number of shares of Common Stock received by SV Life Sciences Fund VI Strategic Partners, L.P. ("SV Life SP LP") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

F7 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date.

F7 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date.

F4 · ownership.nature: The shares are held directly by SV Life SP LP. SV Health Investors, LLC is the Manager of SV Life SP LP. SV Fund VI GP is the general partner of SV Life SP LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. The members of the investment committee of SVLSF VI, LLC are Kate Bingham, Thomas Flynn, James Garvey, Eugene D. Hill, III, Paul LaViolette, and Michael Ross. Each of SV Fund VI GP, SVLSF VI, LLC and the SVLSF VI, LLC investment committee disclaims beneficial ownership of the shares owned directly by SV Life SP LP, except to the extent of any pecuniary interest therein.

SEC source: 0000899243-18-017965 · doc4.xml · derivative · entry 5

SVLSF VI, LLC · CIK 0001717728 · 10% owner

SV Life Sciences Fund VI, L.P. · CIK 0001642251 · 10% owner

SV Life Sciences Fund VI Strategic Partners, L.P. · CIK 0001667605 · 10% owner

SV Life Sciences Fund VI (GP), L.P. · CIK 0001717730 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 2,207,843 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Represents the total number of shares of Common Stock received by SV Life Sciences Fund VI Strategic Partners, L.P. ("SV Life SP LP") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

F7 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date.

F7 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date.

F2 · ownership.nature: The shares are held directly by SV Life LP. SV Health Investors, LLC is the Manager of SV Life LP. SV Life Sciences Fund VI (GP), L.P., ("SV Fund VI GP") is the general partner of SV Life LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. The members of the investment committee of SVLSF VI, LLC are Kate Bingham, Thomas Flynn, James Garvey, Eugene D. Hill, III, Paul LaViolette, and Michael Ross. Each of SV Fund VI GP, SVLSF VI, LLC and the SVLSF VI, LLC investment committee disclaims beneficial ownership of the shares owned directly by SV Life LP, except to the extent of any pecuniary interest therein.

SEC source: 0000899243-18-017965 · doc4.xml · nonDerivative · entry 4

SVLSF VI, LLC · CIK 0001717728 · 10% owner

SV Life Sciences Fund VI, L.P. · CIK 0001642251 · 10% owner

SV Life Sciences Fund VI Strategic Partners, L.P. · CIK 0001667605 · 10% owner

SV Life Sciences Fund VI (GP), L.P. · CIK 0001717730 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 90,573

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: Represents the total number of shares of Common Stock received by SV Life SP LP upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.

F4 · ownership.nature: The shares are held directly by SV Life SP LP. SV Health Investors, LLC is the Manager of SV Life SP LP. SV Fund VI GP is the general partner of SV Life SP LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. The members of the investment committee of SVLSF VI, LLC are Kate Bingham, Thomas Flynn, James Garvey, Eugene D. Hill, III, Paul LaViolette, and Michael Ross. Each of SV Fund VI GP, SVLSF VI, LLC and the SVLSF VI, LLC investment committee disclaims beneficial ownership of the shares owned directly by SV Life SP LP, except to the extent of any pecuniary interest therein.

SEC source: 0000899243-18-017965 · doc4.xml · nonDerivative · entry 3

SVLSF VI, LLC · CIK 0001717728 · 10% owner

SV Life Sciences Fund VI, L.P. · CIK 0001642251 · 10% owner

SV Life Sciences Fund VI Strategic Partners, L.P. · CIK 0001667605 · 10% owner

SV Life Sciences Fund VI (GP), L.P. · CIK 0001717730 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,645,454

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Represents the total number of shares of Common Stock received by SV Life LP upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.

F2 · ownership.nature: The shares are held directly by SV Life LP. SV Health Investors, LLC is the Manager of SV Life LP. SV Life Sciences Fund VI (GP), L.P., ("SV Fund VI GP") is the general partner of SV Life LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. The members of the investment committee of SVLSF VI, LLC are Kate Bingham, Thomas Flynn, James Garvey, Eugene D. Hill, III, Paul LaViolette, and Michael Ross. Each of SV Fund VI GP, SVLSF VI, LLC and the SVLSF VI, LLC investment committee disclaims beneficial ownership of the shares owned directly by SV Life LP, except to the extent of any pecuniary interest therein.

SEC source: 0000899243-18-017965 · doc4.xml · nonDerivative · entry 2

SVLSF VI, LLC · CIK 0001717728 · 10% owner

SV Life Sciences Fund VI, L.P. · CIK 0001642251 · 10% owner

SV Life Sciences Fund VI Strategic Partners, L.P. · CIK 0001667605 · 10% owner

SV Life Sciences Fund VI (GP), L.P. · CIK 0001717730 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 75,591

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Represents the total number of shares of Common Stock received by SV Life Sciences Fund VI Strategic Partners, L.P. ("SV Life SP LP") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

F4 · ownership.nature: The shares are held directly by SV Life SP LP. SV Health Investors, LLC is the Manager of SV Life SP LP. SV Fund VI GP is the general partner of SV Life SP LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. The members of the investment committee of SVLSF VI, LLC are Kate Bingham, Thomas Flynn, James Garvey, Eugene D. Hill, III, Paul LaViolette, and Michael Ross. Each of SV Fund VI GP, SVLSF VI, LLC and the SVLSF VI, LLC investment committee disclaims beneficial ownership of the shares owned directly by SV Life SP LP, except to the extent of any pecuniary interest therein.

SEC source: 0000899243-18-017965 · doc4.xml · nonDerivative · entry 1

SVLSF VI, LLC · CIK 0001717728 · 10% owner

SV Life Sciences Fund VI, L.P. · CIK 0001642251 · 10% owner

SV Life Sciences Fund VI Strategic Partners, L.P. · CIK 0001667605 · 10% owner

SV Life Sciences Fund VI (GP), L.P. · CIK 0001717730 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,207,843

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents the total number of shares of Common Stock received by SV Life Sciences Fund VI, L.P. ("SV Life LP") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

F2 · ownership.nature: The shares are held directly by SV Life LP. SV Health Investors, LLC is the Manager of SV Life LP. SV Life Sciences Fund VI (GP), L.P., ("SV Fund VI GP") is the general partner of SV Life LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. The members of the investment committee of SVLSF VI, LLC are Kate Bingham, Thomas Flynn, James Garvey, Eugene D. Hill, III, Paul LaViolette, and Michael Ross. Each of SV Fund VI GP, SVLSF VI, LLC and the SVLSF VI, LLC investment committee disclaims beneficial ownership of the shares owned directly by SV Life LP, except to the extent of any pecuniary interest therein.